Ahmed valve for secondary glaucoma in patients with hereditary transthyretin amyloidosis

Objective To evaluate the surgical outcomes of patients with hereditary transthyretin amyloidosis (TTR-FAP) who underwent Ahmed glaucoma valve (AGV) implantation. Methods A retrospective cohort study was performed on patients with a diagnosis of TTR-FAP secondary glaucoma, who underwent AGV implanta...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2022-01, Vol.36 (1), p.111-118
Main Authors: Marta, Ana, Vieira, Rita, Figueiredo, Ana, Reis, Rita, Sampaio, Isabel, Beirão, João Melo, Menéres, Maria João
Format: Article
Language:English
Subjects:
692/700/565/545
706/648/160
Amyloid Neuropathies, Familial
Amyloidosis
Complications
Correlation analysis
Follow-Up Studies
Glaucoma
Glaucoma - etiology
Glaucoma - surgery
Glaucoma Drainage Implants - adverse effects
Humans
Intraocular Pressure
Laboratory Medicine
Medicine
Medicine & Public Health
Ophthalmology
Patients
Pharmaceutical Sciences/Technology
Postoperative
Postoperative Complications - surgery
Prosthesis Implantation - adverse effects
Retrospective Studies
Success
Surgery
Surgical Oncology
Survival analysis
Transthyretin
Treatment Outcome
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the surgical outcomes of patients with hereditary transthyretin amyloidosis (TTR-FAP) who underwent Ahmed glaucoma valve (AGV) implantation. Methods A retrospective cohort study was performed on patients with a diagnosis of TTR-FAP secondary glaucoma, who underwent AGV implantation in our department, between November 2010 and July 2019. The cumulative probability of treatment success was measured with Kaplan-Meier survival analysis. The primary outcome was success, defined as intraocular pressure (IOP) ≥ 6 mmHg and ≤21 mmHg with or without medication, with no need for further glaucoma surgery and without loss of light perception at last follow-up. Secondary outcomes were postoperative IOP, number of IOP-lowering medications, and rates of complications. Results The study included 114 eyes of 87 patients. The mean follow-up duration was 3.81 ± 2.11 years (y) [range, 1.00–8.28 y]. Compared to the preoperative values, the mean IOP was reduced from 28.20 ± 7.01 to 12.87 ± 3.76 mmHg at the final visit ( p  
ISSN:0950-222X
1476-5454
DOI:10.1038/s41433-021-01443-y